Acrivon Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Acrivon Therapeutics, Inc. (ACRV) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$78.01 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-19
- Acrivon Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$78.01M.
- Acrivon Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$80.70M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$78.01M 10-K · filed 2026-03-19 |
| 2024-12-31 | -$80.70M 10-K · filed 2026-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |